Emcure Pharmaceuticals Limited (BOM:544210)

Market Cap	262.60B
Revenue (ttm)	81.62B
Net Income (ttm)	7.44B
Shares Out	n/a
EPS (ttm)	39.35
PE Ratio	35.29
Forward PE	25.73
Dividend	n/a
Ex-Dividend Date	n/a

Volume	4,341
Average Volume	9,368
Open	1,449.20
Previous Close	1,398.80
Day's Range	1,373.00 - 1,449.20
52-Week Range	890.00 - 1,577.50
Beta	n/a
RSI	52.24
Earnings Date	Aug 5, 2025

About Nuvei

Emcure Pharmaceuticals Limited develops, manufactures, and markets pharmaceutical products worldwide. It offers products in various therapeutic areas, such gynecology, anti-infectives, pain/analgesics, VMN, blood-related, oncology, respiratory, HIV antivirals, gastro, anti-diabetic, neuro, and cardiovascular. It provides its products under Orofer XT, Tenectase, Pause, Metpure XL, Orofer FCM, and Proxym brand names. Emcure Pharmaceuticals Limited was incorporated in 1981 and is based in Pune, India.

• Industry: Pharmaceutical Preparations
• Founded: 1981
• Employees: 10,852
• Stock Exchange: Bombay Stock Exchange
• Ticker Symbol: 544210

Financial Performance

In 2024, Emcure Pharmaceuticals's revenue was 78.96 billion, an increase of 18.59% compared to the previous year's 66.58 billion. Earnings were 6.81 billion, an increase of 36.76%.